Table 1 Details of the CRC and EC studies used in this analysis.
Study | Case sampling frame | Control sampling fram | Genotyping Platform | Cases | Controls | ||
|---|---|---|---|---|---|---|---|
CRC GWAS | |||||||
1 | UK1-CORGI | Colorectal Tumour Gene Identification Consortium | England; Genetics clinic-based, with family history of CRC | England; spouses and partners of cases with no personal or family history of colorectal neoplasia | Illumina Hap550 | 888 | 899 |
2 | Scotland1 | Scotland | Scotland; population based CRC cases, age <55 | Scotland; from NHS registers matched by age and region | Illumina HumanHap300 and Illumina HumanHap240S | 973 | 998 |
3 | VQ | VICTOR/QUASAR2 | UK; CRC cases enrolled in chemotherapy clinical trials (NSAID and monoclonal antibody) | Illumina HumanHap300, Illumina HumanHap270, Illumina Human 1.2MDuo | 1894 | 2674 | |
WTCCC2 BC58 | UK 1958 Birth Cohort | UK; population based controls, born within one week in 1958 | Illumina 1.2M | ||||
4 | CFR1 | Colon Cancer Family Registry Phase1 | USA and Australia; cases from cancer registries | USA and Australia; population based controls, no family history | Illumina Human1M | 1175 | 999 |
5 | CFR2 | Colon Cancer Family Registry Phase 2 | USA and Australia; cases from cancer registries | Illumina Human1M | 795 | ||
CGEMS prostate | Cancer Genetic Markers of Susceptibility (Prostate) | USA; population based cancer free controls from prostate study | Illumina HumanHap550 | 1101 | |||
EC GWAS | |||||||
6 | NSECG | National Study of Endometrial Cancer Genetics | UK; population based cases | Illumina660WQuads, HumanHap550 | 925 | ||
CGEMS breast | Cancer Genetic Markers of Susceptibility (Breast) | USA; population based cancer free controls from breast study | Illumina HumanHap550 | 1141 | |||
7 | ANECS | Australian National Endometrial Cancer Study | Australia; population based cases | Illumina 610K | 606 | ||
QIMR | Queensland Institute of Medical Research | Australia; parents of participants in adolescent twin study | Illumina 610K | 1846 | |||
HCS | Hunter Community Study | Australia; population-based cohort | Illumina 610K | 1237 | |||
8 | SEARCH | UK Studies of Epidemiology and Risk factors in Cancer Heredity | England; population based cases via cancer registries, age <69 | Illumina 610K | 681 | ||
WTCCC2 NBS | UK; population based controls identified through National Blood Service | Illumina 1.2M | 2501 | ||||
EC COGS | |||||||
9 | ANECS | Australian National Endometrial Cancer Study | Australia; population based cases | Illumina Infinium iSelect | 373 | ||
NECS | Newcastle Endometrial Cancer Study | Australia; hospital-based cases | Illumina Infinium iSelect | 165 | |||
ABCFS | Australian Breast Cancer Family Study | Australia; from electoral rolls | Illumina Infinium iSelect | 443 | |||
AOCS | Australian Ovarian Cancer Study | Australia; population-based, from electoral rolls | Illumina Infinium iSelect | 817 | |||
MCCS | Melbourne Collaborative Cohort Study | Australia; random sample from initial cohort | Illumina Infinium iSelect | 437 | |||
10 | SEARCH | UK Studies of Epidemiology and Risk factors in Cancer Heredity | England; population based cases | England; population based controls | Illumina Infinium iSelect | 773 | 7,510 |
11 | NSECG | National Study of Endometrial Cancer Genetics | England; population based cases | Illumina Infinium iSelect | 965 | ||
BBCS | British Breast Cancer Study | UK; friend, sister-in-law, daughter-in-law or other non-blood relative of breast cancer case | Illumina Infinium iSelect | 1,353 | |||
SBCS | Sheffield Breast Cancer Study | UK; women attending Sheffield Mammography Screening, with no breast lesion | Illumina Infinium iSelect | 835 | |||
UKBGS | UK Breakthrough Generations Study | UK; women without breast lesions selected from BGS cohort | Illumina Infinium iSelect | 449 | |||
12 | MECS | Mayo Endometrial Cancer Study | USA; Hospital based cases | Illumina Infinium iSelect | 221 | ||
MCBCS | Mayo Clinic Breast Cancer Study | USA; Cancer-free women presenting for general medical examination | Illumina Infinium iSelect | 1,762 | |||
MCBCS/MCOCCCS | Mayo Clinic Ovarian Cancer Case-Control Study | USA; Cancer-free women presenting for general medical examination | Illumina Infinium iSelect | 593 | |||
13 | LES | Leuven Endometrial Cancer Study | Belgium; hospital based cases | Illumina Infinium iSelect | 321 | ||
LMBC | Leuven Multidisciplinary Breast Centre | Belgium; controls from blood donors | Illumina Infinium iSelect | 1,382 | |||
14 | BECS/HJECS | Bavarian/Hannover-Jena Endometrial Cancer Study | Germany; population and hospital-based cases | Illumina Infinium iSelect | 137 | ||
BBCC | Bavarian Breast Cancer Cases and Controls | Germany; healthy women >55yrs from newspaper advertisement | Illumina Infinium iSelect | 441 | |||
BSUCH | Breast Cancer Study of the University Clinic Heidelberg | Germany; female blood donors | Illumina Infinium iSelect | 920 | |||
ESTHER | ESTHER Breast Cancer Study | Germany; random sample from routine health check-up | Illumina Infinium iSelect | 486 | |||
GC-HBOC | German Consortium for Hereditary Breast & Ovarian Cancer | Germany; KORA study | Illumina Infinium iSelect | 138 | |||
GENICA | Gene Environment Interaction and Breast Cancer in Germany | Germany; random address sample | Illumina Infinium iSelect | 420 | |||
MARIE | Mammary Carcinoma Risk Factor Investigation | Germany; randomly drawn from population registries | Illumina Infinium iSelect | 1,712 | |||
15 | MoMaTEC | Molecular Markers in Treatment of Endometrial Cancer | Norway; population based cases | Illumina Infinium iSelect | 599 | ||
NBCS | Norwegian Breast Cancer Study | Norway; attendees at Norwegian Breast Cancer Screening Program | Illumina Infinium iSelect | 234 | |||
16 | CAHRES/RENDOCAS | Cancer Hormone Replacement Epidemiology | Sweden; population based cases | Illumina Infinium iSelect | 543 | ||
RENDOCAS | Registry of Endometrial Cancer in Sweden | Sweden; hospital based cases | Illumina Infinium iSelect | 233 | |||
KARBAC | Karolinska Breast Cancer Study | Sweden; blood donors | Illumina Infinium iSelect | 6,917 | |||
pKARMA | Karolinska Mammography Project for Risk Prediction of Breast Cancer | Sweden; cancer-free participants of mammography screening | Illumina Infinium iSelect | 6,917 | |||
